Supply Chain | April 17, 2026
Syntegon reports record FY25 Results; revenue rises 10% to €1.75 billion
The company allocated €56 million to research and development for next-generation line solutions
The company allocated €56 million to research and development for next-generation line solutions
The reports will now be shared with relevant ministries and departments as a guidance framework
The India FMCG business showed a sequential recovery and is expected to post high-single digit growth
Searches for diabetes, heart conditions, and metabolism-related risks are rising sharply, with Tier 2 cities outpacing metros in specialist consultations
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI
FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors
The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
Giredestrant shows promise despite missing primary goal
Subscribe To Our Newsletter & Stay Updated
